Curated News
By: NewsRamp Editorial Staff
August 08, 2024
Clene (NASDAQ: CLNN) Releases Q2 2024 Financial Results and Updates on CNM-Au8(R) Programs
Discuss on Reddit
Discuss on SubstackTLDR
- Clene (NASDAQ: CLNN) released Q2 2024 financial results and provided updates on CNM-Au8(R) programs for ALS and Rett Syndrome.
- CNM-Au8(R) is an investigational therapy that targets mitochondrial function and reduces oxidative stress to improve neuronal function.
- Clene's focus on improving mitochondrial health and protecting neuronal function aims to help patients with ALS and MS, prioritizing those for whom time is critical.
- CNM-Au8(R) is a first-in-class therapy that targets mitochondrial function, offering hope for improving treatment outcomes for neurodegenerative diseases.
Impact - Why it Matters
This news matters because Clene's potential new drug application could offer hope to patients with ALS and Rett Syndrome, addressing critical time needs for treatment.
Summary
Clene (NASDAQ: CLNN) and its subsidiary Clene Nanomedicine Inc. released its Q2 2024 financial results and provided updates on its CNM-Au8(R) programs for treating ALS and Rett Syndrome. The company is optimistic about submitting a new drug application later this year to help patients with critical time needs.
Clene is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including ALS, Parkinson’s, and MS. CNM-Au8(R) is an investigational therapy that targets mitochondrial function and NAD pathway while reducing oxidative stress. The company's utmost priority is to help patients and their families for whom time is critical.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Clene (NASDAQ: CLNN) Releases Q2 2024 Financial Results and Updates on CNM-Au8(R) Programs
